26.01.2026 • News

Borealis Pumps €49 Million into Circular Technologies in Germany

Borealis is investing €49 million in its Burghausen site to scale up Borstar Nextension polypropylene production, enabling high‑performance monomaterial solutions that support recyclability and compliance with upcoming EU packaging regulations across packaging, healthcare, mobility, and fiber applications.

Borealis Burghausen site
Borealis invests €49 million in its production location Burghausen, to accelerate commercial scale-up of Borstar Nextension polypropylene technology.
© Borealis

Borealis announces a €49 million strategic investment to scale up production of Borstar Nextension polypropylene (PP) at its manufacturing site in Burghausen, Germany. This will expand commercial production of next-generation single-site polypropylene (ssPP) grades that deliver enhanced purity, processability, and performance - supporting customers in key sectors including packaging, healthcare, mobility, and fibers, to meet evolving market and regulatory demands.

The investment will support the transition to high-performance monomaterial PP solutions. By integrating a tailored combination of performance properties into a single PP material, Borstar Nextension technology facilitates material substitution in complex multilayer structures – supporting design for circularity, reducing weight, and improving overall performance.

“By scaling up Borstar Nextension PP production, we empower our customers to stay ahead in a rapidly changing regulatory and market landscape. It’s another example of our commitment to increase the availability of innovative, recyclable polymer materials suitable for a wide range of applications across multiple industries,” says Craig Arnold, Borealis EVP Polyolefins, Circular Economy Solutions and Base Chemicals.

Company

Borealis AG

Wagramer Str. 17 -19
1220 Vienna
Austria

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.